InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPRFree Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.

Several other brokerages also recently commented on NSPR. Piper Sandler restated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital started coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

Get Our Latest Stock Report on NSPR

InspireMD Stock Performance

NYSE:NSPR opened at $2.71 on Friday. The company has a market capitalization of $70.69 million, a price-to-earnings ratio of -3.61 and a beta of 0.99. The company has a 50-day moving average of $2.74 and a 200-day moving average of $2.70. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42.

InspireMD (NYSE:NSPRGet Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The firm had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter last year, the company earned ($0.15) earnings per share. Sell-side analysts forecast that InspireMD will post -0.79 EPS for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPRFree Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

Read More

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.